Abstract
Background:
Lebrikizumab is a monoclonal antibody targeting interleukin 13 (IL-13), a key cytokine in the pathogenesis of atopic dermatitis (AD). It was approved by the Food and Drug Administration (FDA) in 2024 for the treatment of moderate-to-severe AD in patients aged ≥12 years.
Data sources:
A literature search was conducted through October 2025 using PubMed and ClinicalTrials.gov with the terms “lebrikizumab,” “Ebglyss,” “lebrikizumab clinical trials,” and “lebrikizumab atopic dermatitis.” Phase I to III clinical trials, post-approval studies, and FDA package insert were reviewed.
Study selection and data extraction:
Trials evaluating lebrikizumab in patients with AD were included. Data were extracted on study design, pharmacology, efficacy outcomes, and safety events. One phase I, 2 phase II, and 6 phase III studies were summarized along with real-world evidence.
Data synthesis:
Lebrikizumab had dose-dependent reductions in AD severity and pruritus, with improvements observed as early as day 2. Across phase III trials, 33% to 43% of lebrikizumab-treated patients achieved an Investigator’s Global Assessment Score (IGA) 0/1 compared with 11% or less with placebo. Adverse events were mild; conjunctivitis occurred less frequently than with agents targeting both IL-4 and IL-13.
Relevance to patient care and clinical practice in comparison to existing drugs:
As a selective IL-13 inhibitor, lebrikizumab offers comparable efficacy with reduced ocular adverse events relative to dupilumab. Its pharmacologic distinctions from tralokinumab may carry clinical implications.
Conclusion:
Lebrikizumab is an effective and well-tolerated biologic with rapid onset of action and favorable safety for treatment of moderate-to-severe AD.
Get full access to this article
View all access options for this article.